Antifungal rapamycin analogues with reduced immunosuppressive activity

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 13, 2000, Pages 1405-1408

  Dickman, Daniel A ^a   Ding, Hong ^a   Li, Qun ^a   Nilius, Angela M ^a   Balli, Darlene J ^a   Ballaron, Stephen J ^a   Trevillyan, James M ^a   Smith, Morey L ^a   Seif, Louis S ^a   Kim, Ki ^a   Sarthy, Aparna ^a   Goldman, Robert C ^a   Plattner, Jacob J ^a   Bennani, Youssef L ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CARBAMIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ANTIFUNGAL ACTIVITY; ARTICLE; DRUG SYNTHESIS; NONHUMAN; SACCHAROMYCES CEREVISIAE; STRUCTURE ANALYSIS;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; BIOPHARMACEUTICS; CANDIDA; CHEMISTRY, PHARMACEUTICAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; SIGNAL TRANSDUCTION; SIROLIMUS;

SACCHAROMYCES CEREVISIAE;

EID: 0034601227     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00184-0     Document Type: Article

References (29)

1. (a) Kauffman, C. A.; Carver, P. L. Drugs 1997, 53, 539.
2. (b) Sternberg, S. Science 1994, 266, 1632.
3. (a) Alexander, B. D.; Perfect, J. R. Drugs 1997, 54, 657.
4. (b) Klepsner, M. E.; Ernst, E. J.; Pfaller, M. A. Trends Microbiol. 1997, 5, 372.
5. (a) Fromling, R. A. Drugs News Reports 1997, 10, 170.
6. (b) Turner, W. W.; Rodriguez, M. J. Current Pharmac. Design 1996, 2, 209.
7. (c) Lyman, C. A.; Walsh, T. J. Drugs 1992, 44, 9.
8. (a) Sanati, H; Belanger, P.; Fratti, R.; Ghannoum, M. Antimicrob. Agents Chemother. 1997, 2492.
9. (b) Lutz, J. E.; Clemons, K. V.; Aristizabal, B. H.; Stevens, D. A. Antimicrob. Agents Chemother. 1997, 1558.
10. (a) Abruzzo, G. K.; Flattery, A. M; Gill, C. J.; Kong L.; Smith, J. G.; Pikounis, V. B.; Balkovec, J. M.; Boufard, A. F.; Dropinski, J. F.; Rosen, H.; Kropp, H.; Bartizal, K. Antimicrob. Agents Chemother. 1997, 2333.
11. (b) Jamison, J. A.; LaGrandeur, L. M.; Rodriguez, M. J.; Turner, W. W.; Zeckner, D. J. J. Antibiotics 1998, 51, 239.
12. Vezina C., Kudelski A., Sehgal S.N. J. Antibiotics. 28:1975;721.
13. Schreiber S.L., Liu J., Albers M.W., Karmacharya R., Koh E., Martin P.K., Rosen M.K., Standaert R.F., Wandless T.J. Transplan. Proc. 23:1991;2839.
14. Brattstrom, C.; Sawe, J.; Tyden, G.; Herlenius, G.; Claesson, K.; Zimmerman, J.; Groth, C.-G. Therapeutic Drug Monitoring, 1997, 19, Lippincott-Raven: Philadelphia PA.
15. Nicolaou, K. C.; Piscopio, A. D.; Bertinato, P., Chakraborty, K.; Minowa, N.; Koide K. Chem. Eur. J. 1995, 318.
16. Staunton J., Wilkinson B. Chem. Rev. 97:1997;2611.
17. (a) Brown, E. J.; Schreiber, S. L. Cell 1996, 86, 517.
18. (b) Molnar-Kimber, K. L. Transplan. Proc. 1996, 28, 964.
19. (c) Brazelton, T. R.; Morris, R. E. Curr. Opinion in Immunology 1996, 8, 710.
20. (a) Weisman, R.; Choder, M.; Koltin, Y. J. Bacteriol. 1997, 6324.
21. (b) Beretta, L.; Gingras, A.-C.; Svitkin, Y. V.; Hall, M. N.; Enberg, N. EMBO 1996, 15, 658.
22. (a) Caufield, C. E.; Musser, J. H., Rinker, J. M. US5,023,262.
23. (b) Luengo, J. I.; Yamashita, D. S.; Dunnington, D.; Beck, A. K.; Rozamus, L. W.; Yen, H.-K.; Bossard, M. J.; Levy, M. A.; Hand, A.; Newman-Tarr; T.; Badger, A.; Faucette, L.; Johnson, R. K.; D'Allessio, Porter, T.; Shu, A. Y. L.; Heys, R.; Choi, J.; Kongsaeree, P.; Clardy, J.; Holt, D. A. Chemistry Biology 1995; 471.
24. (c) Ocain, T. D.; Longhi D.; Steffan; R. J.; Caccese, R. G.; Sehgal, S. N. Biochem. Biophys. Res. Commun. 1993, 192, 1340.
25. Or, Y. S.; Luly, J. R.; Wagner, R. US 5,672,605 and references cited therein.
26. Holt, D. A. Keenan, T. P.; Clackson, T. P.; Rozamus, L.; Yang, W.; Gilman, M. Z. WO9802441-A2.
27. 13b The epimeric products were purfied by preparative HPLC (acetone:hexane gradient from 1:10 to 20:1 ratios). Compounds 13, 14 and 15 were synthesized from 1 and acetyl hydroxamic acid and N-hydroxyurea. Substituted N-hydroxycarbamates and N-hydroxyureas were prepared by reaction of the corresponding chloroformates in a stirred biphasic water-dichloromethane solution in the presence of 2.0 equiv of hydroxylamine-HCl and 3.0 equiv sodium bicarbonate 12 h; the aqueous layer was acidified with phosphoric acid and the organic layer was concentrated to yield the N-hydroxycarbamate. Compounds 23 and 25, were prepared by reaction of N-carbonylphenoxy-hydroxylamine with piperidine and morpholine, respectively. Compound 24 was formed as a side product when water was present in the Lewis-acid catalyzed reaction mixture. All compounds were characterized by NMR and HRMS.
28. Heitman J., Movva N.R., Hall M. Science. 253:1991;905.
29. Wong G.K., Griffith S., Kojima I., Demain A.L. J. Antibiotics. 51:1998;405.